Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies.

Loading...
Thumbnail Image
Identifiers

Publication date

2022

Start date of the public exhibition period

End date of the public exhibition period

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Journal of Clinical Medicine
Metrics
Google Scholar

Research Projects

Organizational Units

Journal Issue

Abstract

Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies.

Doctoral program

Description

Keywords

Beta-adrenergic receptor antagonist, Propranolol, Chemotherapy, Combination cancer therapy, Apoptosis, Inflammation, Angiogenesis, Biomarker

Citation